Lupin Earns Great Place To Work® Certification for 2026-27
Global pharmaceutical major Lupin Limited announced today that it has received the Great Place To Work® certification for 2026-27. This recognition positions Lupin among select pharmaceutical companies to achieve this certification through a global study that spanned all its subsidiaries and geographies.The achievement highlights the organization's dedication to employee experience and its inclusive culture. Lupin recorded an 85% participation rate from its employees, whose input was central to the evaluation process.
Yashwant Mahadik, President - Global Human Resources, Lupin, commented on the recognition, stating, "We are honored to receive this global certification from Great Place To Work®. It reflects the strength of our inclusive and values-driven workplace culture, where employees across geographies feel respected, valued, and empowered to perform at their best. We remain committed to further strengthening our culture and continuously enhancing the employee experience across all our locations."
Lupin has a permanent workforce exceeding 24,000 professionals across various functions and geographies. The company reported specific investments for the financial year 25.
| Metric | Value |
|---|---|
| Employee Benefits Investment (FY25) | INR 40 billion |
| Employee Training Hours (FY25) | 1,253,456 hours |
Headquartered in Mumbai, India, Lupin Limited operates as a global pharmaceutical leader, distributing products in over 100 markets. The company specializes in pharmaceutical products, encompassing branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Lupin maintains a strong presence in both India and the U.S. across several therapeutic areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health.
Lupin operates 15 state-of-the-art manufacturing sites and 7 research centers globally, in addition to its dedicated workforce of over 24,000 professionals. The company is focused on enhancing patient health outcomes through its subsidiaries: Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
LUPIN Stock Price Movement
Shares of Lupin Limited are edging higher to ₹2291.6 as of 10:58 AM today, gaining 0.51%. The stock is currently trading with a notable volume of 156,131 shares in the live market.Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.